Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 7/20 | 0.33 |
| ▸ | CA9 | Q16790 | 7/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535345 | 0.90 | LGALS3 (0.38) | LGALS3F10MAPK1CA12CA9 | |
| SCHEMBL29535299 | 0.90 | MAPK1 (0.40) | LGALS3F10MAPK1CA12CA9 | |
| SCHEMBL16728933 | 0.90 | MAPK1 (0.40) | LGALS3F10MAPK1CA12CA9 | |
| SCHEMBL16729068 | 0.87 | LGALS3 (0.36) | LGALS3F10MAPK1CA12CA9 | |
| SCHEMBL29535351 | 0.81 | MAPK1 (0.53) | LGALS3MAPK1CA9CA1CA2 | |
| SCHEMBL29535303 | 0.81 | MAPK1 (0.53) | LGALS3MAPK1CA9CA1CA2 | |
| SCHEMBL1923003 | 0.80 | FGF1 (0.36) | LGALS3CA12CA9CA1CA2 | |
| SCHEMBL29534894 | 0.78 | F10 (0.43) | LGALS3F10CA2 | |
| SCHEMBL2186684 | 0.77 | LGALS3 (0.38) | LGALS3CA12CA9CA1CA2 | |
| SCHEMBL3914085 | 0.77 | LGALS3 (0.38) | LGALS3CA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366853-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | EXTHERA MEDICAL CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| US-12090261-B2 | Method for modulating endothelial glycocalyx structure | EXTHERA MEDICAL CORPORATION (US) | 2024-09-17 | — | — | US | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |